Ahead of Shire buyout, Takeda sells joint venture and reportedly plans $20B bond deal

Japanese pharmaceutical giant Takeda is boosting its finances ahead of its costly acquisition of Shire plc, selling its stake in a Chinese joint venture for $280 million and reportedly planning a record $20 billion bond deal. Takeda announced Monday that it had sold its majority stake in a joint venture called Guangdong Techpool Bio-Pharma Co., which sells drugs for pancreatitis and stroke. The move is part of a broader effort by Takeda to ditch assets outside of its core focus areas, including…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news